Cell Genesys
Executive Summary
Homologous recombination technology R&D start-up completes a $7 mil. first round of venture capital financing. Investors include Stanford University. "We have implemented an aggressive product development plan, with particular emphasis on genetic modification of cells to allow the manufacture of human therapeutic proteins and genetic modification of cells to create 'universal donor cell' transplant products," the Foster City, California-based company says.